Live Analyst Rating Changes 31576 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Andrew Semple
VF

Andrew Semple

Ventum Financial
Wall Street Analyst
★☆☆☆☆
#3012
on 13Foresight · ranked by our own returns
30%
Success Rate
-12.7%
Average Return
3 of 10 calls profitable · -28.1% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 30% of Andrew Semple's ratings turned a profit when each position was held for 1 year — averaging -12.7% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

1 Buy 0 Hold 0 Sell
Andrew's Stock Coverage 15 ratings · 2026-09-11
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
TSE:DB
Decibel Cannabis Company
 Apr 22, 2025 BUY Strong Buy
+86.0% avg upside
4 analysts
$0.20
87.89% Downside
 +107.7% ·
TSE:VEXT
Vext Science
 Apr 01, 2025 BUY Strong Buy
+426.9% avg upside
3 analysts
$0.50
85.14% Upside
 +43.2% ·
TSE:GLAS.A.USD
Glass House Brands
 Mar 26, 2025 BUY Strong Buy
4 analysts
$12.00
 · ·
TSE:AYR.A
Ayr Wellness
 Mar 07, 2025 HOLD Strong Buy
+24757.9% avg upside
9 analysts
$0.40
158.16% Upside
 -48.3% ·
TRLV
Trulieve Cannabis
 Feb 28, 2025 BUY Strong Buy
+96.8% avg upside
15 analysts
$13.76
21.53% Upside
 +50.3% ·
TSE:AAWH.USD
Ascend Wellness Holdings LLC
 Jul 16, 2024 BUY Strong Buy
6 analysts
$3.50
 · ·
TSE:HITI
High Tide
 Jun 14, 2024 BUY Strong Buy
+96.8% avg upside
9 analysts
$8.50
140.89% Upside
 -8.6% ·
TSE:AEP
Atlas Engineered Products Ltd
 May 30, 2024 BUY Strong Buy
+166.1% avg upside
2 analysts
$2.00
222.52% Upside
 -28.2% ·
TSE:CL
Cresco Labs
 May 15, 2024 BUY Strong Buy
+438.3% avg upside
13 analysts
$3.75
271.26% Upside
 · ·
CBSTQ
Cannabist Company Holdings
 May 10, 2024 HOLD Strong Buy
+5188603.7% avg upside
5 analysts
$0.33
325871.02% Upside
 · ·
TSE:TSND
TerrAscend Corp
 May 10, 2024 BUY Strong Buy
+337.9% avg upside
8 analysts
$2.75
212.58% Upside
 -78.0% ·
TSE:JUSH
Jushi Holdings
 May 10, 2024 HOLD Buy
+381.7% avg upside
7 analysts
$1.30
66.61% Upside
 -44.1% ·
MRMD
MariMed
 May 09, 2024 BUY Buy
+1563.5% avg upside
3 analysts
$0.40
402.17% Upside
 -65.5% ·
TSE:GTII
Green Thumb Industries
 May 09, 2024 BUY Strong Buy
+106.5% avg upside
15 analysts
$23.00
124.12% Upside
 -55.6% ·
TSE:VRNO
Verano Holdings
 May 08, 2024 BUY Strong Buy
+147.6% avg upside
8 analysts
$11.00
33.27% Upside
 · ·
🔒 10 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Andrew Semple — Frequently Asked Questions
How accurate are Andrew Semple's stock ratings?
Based on the calls 13Foresight could measure, about 30% of Andrew's ratings were profitable over a one-year hold, with an average return of -12.7% per rating, or -28.1% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Andrew ranked on 13Foresight?
Andrew Semple is currently ranked #3012 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Andrew cover?
Andrew most recently has ratings on TSE:DB, TSE:VEXT, TSE:GLAS.A.USD, TSE:AYR.A, TRLV, TSE:AAWH.USD, TSE:HITI, TSE:AEP, TSE:CL, CBSTQ, TSE:TSND, TSE:JUSH and 3 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.